Gladius Pharmaceuticals Overview

  • Founded
  • 2015
Founded
  • Status
  • Private
  • Employees
  • 6
Employees
  • Latest Deal Type
  • Early Stage VC
  • Latest Deal Amount
  • $3.03M
Latest Deal Amount
  • Investors
  • 3

Gladius Pharmaceuticals General Information

Description

Developer of antibiotics designed for empiric treatment of Gram-negative infections. The company's antibiotics has demonstrated broad-spectrum efficacy against Gram-negative pathogens and are capable of replacing older generation cephalosporins, enabling physicians to treat bacterial infections.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Primary Office
  • 500 Boulevard Cartier Ouest
  • Laval, Quebec H7V 5B7
  • Canada
+1 (514) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Gladius Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC 27-Nov-2018 $3.03M 00.000 Completed Generating Revenue
1. Early Stage VC (Series A) 24-Jun-2015 00.000 00.000 Completed Generating Revenue
To view Gladius Pharmaceuticals’s complete valuation and funding history, request access »

Gladius Pharmaceuticals Executive Team (6)

Name Title Board Seat Contact Info
Domenic Luca Chief Financial Officer & Vice President of Finance
Larry Sutton Ph.D Scientific Founder, Chief Scientific Officer & Board Member
Marc Vidal Ph.D Head of Chemistry & Board Member
Joaquim Trias Ph.D Chief Scientific Officer
Paul Truex Executive Chairman & Board Member
You’re viewing 5 of 6 executive team members. Get the full list »

Gladius Pharmaceuticals Board Members (7)

Name Representing Role Since
Daniel Hétu MD Lumira Ventures Board Member 000 0000
Larry Sutton Ph.D Gladius Pharmaceuticals Scientific Founder, Chief Scientific Officer & Board Member 000 0000
Marc Vidal Ph.D Gladius Pharmaceuticals Head of Chemistry & Board Member 000 0000
Nathalie Chauret Gladius Pharmaceuticals Board Member 000 0000
Paul Truex Self Executive Chairman & Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

Gladius Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Gladius Pharmaceuticals Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Fonds de solidarité FTQ PE/Buyout Minority 000 0000 000000 0
Lumira Ventures Venture Capital Minority 000 0000 000000 0
SR One Corporate Venture Capital Minority 000 0000 000000 0
To view Gladius Pharmaceuticals’s complete investors history, request access »